Merck & Co. Inc.

KEYTRUDA franchise keeps powering ahead at 10% growth, and WINREVAIR's 141% ramp is validating the cardiovascular expansion thesis. But GARDASIL's 24% decline in China is a structural headwind, not a blip. The $70B+ domestic manufacturing commitment signals long-term confidence but compresses near-term margins.